Innoviva (INVA) Net Income towards Common Stockholders (2010 - 2026)

Innoviva's (INVA) quarterly Net Income towards Common Stockholders came in at $186.6 million in Q1 2026, up 500.51% YoY from $31.1 million in Q1 2025, and up 1191.71% on a QoQ basis from -$17.1 million in Q4 2025.

Innoviva (INVA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Innoviva (INVA) has 17 years of Net Income towards Common Stockholders data on file, last reported at $186.6 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 500.51% year-over-year to $186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340.2 million (up 223.11% YoY) and the FY2025 annual result came in at $326.9 million, up 1297.32% from the prior year.
  • Net Income towards Common Stockholders advanced to $186.6 million in Q1 2026, from -$17.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $282.2 million in Q3 2022 to a low of -$198.2 million in Q4 2024.
  • A 5-year average of $31.0 million and a median of $3.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 2809.77% — and 2025, when it soared 3359.15%.
  • Tracing INVA's Net Income towards Common Stockholders over 5 years: stood at -$15.9 million in 2022, then jumped by 36.0% to -$10.2 million in 2023, then tumbled by 1847.08% to -$198.2 million in 2024, then surged by 91.38% to -$17.1 million in 2025, then jumped by 1191.71% to $186.6 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at $186.6 million (Q1 2026), -$17.1 million (Q4 2025), and $107.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 472.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -644.37 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 237.01 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 930.12
7 Royalty Pharma 33.72 Bn 35.84 Bn - 81.49 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 164.49 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -13.27 Mn
10 Innoviva 1.54 Bn 968.79 Mn 90.62 Mn -83.42 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -83.42 Mn
Mar 31, 2026 186.60 Mn
Dec 31, 2025 -17.09 Mn
Sep 30, 2025 107.03 Mn
Jun 30, 2025 63.69 Mn
Mar 31, 2025 -46.59 Mn
Dec 31, 2024 -198.17 Mn
Sep 30, 2024 3.09 Mn
Jun 30, 2024 -34.69 Mn
Mar 31, 2024 36.52 Mn
Dec 31, 2023 -10.18 Mn
Sep 30, 2023 118.19 Mn
Jun 30, 2023 1.28 Mn
Mar 31, 2023 34.87 Mn
Dec 31, 2022 -15.90 Mn
Sep 30, 2022 282.24 Mn
Jun 30, 2022 939,000.00
Mar 31, 2022 15.77 Mn
Dec 31, 2021 -44.88 Mn
Sep 30, 2021 255.51 Mn